2005

Guidant Announces Full Availability of Cardiac Rhythm Management Product Line Indianapolis, Ind. and St. Paul, Minn. - Guidant Corporation (NYSE: GDT) today announced U.S. Food and Drug...

Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that the company''s board of directors declared a third quarter dividend of $0.10 per share on outstanding common stock. This...

Company Expects to Resume Implants and Distribution by Mid-week Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) said today that it received U.S. Food and Drug Administration (FDA) approval to...

Robert J. Myerburg, M.D., Internationally Recognized Leader in Electrophysiology Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that Dr. Robert J. Myerburg, Professor of...

CE Mark Clears Way for Guidant to Reenter Market Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) said today that it received Conformité Européenne (CE) Mark approval to launch its CONTAK...

Guidant Updates Corrective Actions Regarding Its VENTAK PRIZM AVT, VITALITY AVT, and CONTAK RENEWAL AVT Implantable Cardiac Defibrillators Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) said...

Worldwide implantable defibrillator revenue of $470 million, up 3 percent Worldwide coronary stent revenue of $118 million, down 2 percent Worldwide revenue from emerging businesses of $97...

District Court for Delaware Upholds Validity of Mirowski Patent Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) today announced that it won a key decision in a heart failure device patent...

Indianapolis, Ind. - Guidant Corporation (NYSE: GDT) said today it is voluntarily advising physicians about important safety information regarding certain devices. Guidant apprised FDA of this...

Data From Study Will Support Launch of XIENCE V Coronary Stent System Outside the United States Indianapolis, Ind. and Brussels - Guidant Corporation (NYSE: GDT) today announced that the company...